Immunotherapy for lung cancer in Israel — get 3 top clinic matches with costs

Candidates for immunotherapy in Israel include patients with advanced solid tumors, relapsed blood cancers, or specific genetic markers like MSI-H/dMMR. Eligibility depends on PD-L1 expression levels and the absence of EGFR or ALK mutations, as confirmed by multidisciplinary tumor boards at JCI-accredited centers like Sourasky or Sheba.

• Genetic profile: Patients with PD-L1 levels above 50% are primary candidates for immediate treatment.
• Disease stage: Those with stage 4 non-small cell lung cancer often receive combined immunotherapy and chemotherapy.
• Physical health: Aggressive Tumor-Infiltrating Lymphocyte (TIL) therapy requires patients to be in good physical condition.
• Treatment history: Candidates who have not responded to standard treatments may transition to advanced immunotherapy protocols.

Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center leverage the Foundation One CDx test to identify candidates beyond standard PD-L1 levels. This precision approach allows doctors like Dr. Ari Raphael to offer clinical trial access to patients who might be ineligible for immunotherapy in other regions due to less sensitive diagnostic tools.

Patient Consensus: Success depends heavily on personalized biomarker testing through blood or biopsy. Patients emphasize that while some achieve full remission, physical resilience is vital for protocols like TIL therapy available in Tel Aviv.

Immunotherapy for lung cancer in Israel achieves response rates up to 45% and disease control rates near 60% for non-small cell lung cancer. Leading institutions like Sourasky Medical Center and Sheba Medical Center utilize checkpoint inhibitors and molecular profiling to extend survival for advanced-stage patients.

• Disease control rate: Israeli studies report 60% of patients achieve stable disease or partial response.
• Response efficiency: Advanced checkpoint inhibitors like Keytruda show efficacy rates reaching approximately 45%.
• Diagnostic precision: Mandatory PD-L1 and genetic testing via Foundation One CDx optimize treatment selection.
• Specialized facilities: JCI-accredited Sourasky Medical Center treats 40,000 cancer patients annually with high-tech protocols.

Bookimed Expert Insight: Israeli oncology excels at converting non-responsive tumors through combination protocols. Clinics often pair immunotherapy with precision radiation using the Novalis TrueBeam STx. This synergy aims to trigger a stronger immune response than using drugs alone.

Patient Consensus: Patients emphasize the necessity of advanced molecular testing before starting treatment. Outcomes are often viewed as survival prolongation rather than a permanent cure for advanced stages.

Common side effects of immunotherapy include skin reactions, extreme fatigue, and flu-like symptoms. These immune-related adverse events occur because the treatment stimulates the immune system to attack healthy tissues. Most reactions appear within six months, though some may develop later or become chronic.

• Skin reactions: Affects 7–18% of patients, causing rashes, itching, blistering, or vitiligo.
• Gastrointestinal issues: Colitis symptoms like diarrhea, cramping, and nausea may require steroid treatment.
• Respiratory changes: Pneumonitis causes new coughs or shortness of breath needing immediate reporting.
• Endocrine dysfunction: Thyroid inflammation frequently leads to long-term hormone replacement therapy needs.

Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center utilize Foundation One CDx genetic testing to predict response. This molecular profiling helps specialists like Professor Ofer Merimsky tailor immunotherapy dosages. Individualized protocols may reduce the intensity of common side effects while maintaining high efficacy rates.

Patient Consensus: Fatigue is often the most persistent challenge, described as a deep exhaustion that rest cannot fix. Many patients recommend scheduling two days of recovery after each infusion to manage these energy drops.

Israel is a global leader in lung cancer immunotherapy, offering advanced immune checkpoint inhibitors and pioneering Tumor-Infiltrating Lymphocyte (TIL) therapy. Treatment is heavily biomarker-driven, utilizing Next-Generation Sequencing and PD-L1 testing to personalize protocols for non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer.

• Standard medications: Clinics utilize FDA-approved drugs including Pembrolizumab (Keytruda), Nivolumab (Opdivo), and Atezolizumab (Tecentriq).
• Specialized techniques: Facilities offer genomic profiling, liquid biopsies, and abscopal effect protocols combining immunotherapy with radiation.
• Top institutions: Sourasky Medical Center treats 40,000 cancer patients annually using Novalis TrueBeam STx technology.
• Expert leadership: Doctors like Professor Ofer Merimsky integrate tumor immunology research directly into clinical practice.

Bookimed Expert Insight: Israeli oncology centers like Sheba and Sourasky differentiate themselves by offering TIL therapy outside traditional clinical trials. This is a significant differentiator for Stage 4 patients who have exhausted standard checkpoint inhibitors. Our data shows these JCI-accredited facilities maintain high success rates by using multidisciplinary tumor boards to review every case.

Patient Consensus: Success depends heavily on pre-treatment PD-L1 testing and comprehensive mutation screening for EGFR or ALK. Patients emphasize distinguishing between general lung cancer protocols and specific T-cell therapies when contacting Israeli medical coordinators.

Immunotherapy for lung cancer typically lasts 2 years, often consisting of 35 treatment cycles. The duration varies based on clinical response, with maintenance therapy sometimes extending longer. Treatment may conclude earlier if scans show stable results or if side effects require a change in protocol.

• Treatment cycle length: Cycles usually occur every 2, 3, 4, or 6 weeks via intravenous infusion.
• Initial evaluation window: Surgeons and oncologists typically perform the first definitive scan at 3 months.
• Response timeline: Patients often show early positive responses within 4 to 6 weeks of initiation.
• Discontinuation criteria: Therapy may stop if disease progresses beyond 20% or side effects become intolerable.

Bookimed Expert Insight: Israel's leading oncology centers, like Sourasky Medical Center, utilize Foundation One CDx genomic profiling to tailor these timelines. Instead of a rigid 2-year window, specialists like Professor Ofer Merimsky use liquid biopsies to monitor real-time drug effectiveness. This precision approach helps determine if a patient can safely transition to a monitoring phase earlier or requires extended maintenance cycles.

Patient Consensus: Patients emphasize the importance of completing the full course even when experiencing fatigue. Many note that the immune system needs consistent time to effectively learn how to control cancer cells.

Israel utilizes advanced checkpoint inhibitors including Keytruda, Opdivo, Yervoy, and Tecentriq to treat lung, skin, and blood cancers. Specialized oncology centers like Sourasky Medical Center integrate these drugs with genetic profiling and liquid biopsies to personalize treatment protocols for international patients.

• Core checkpoint inhibitors: Keytruda and Opdivo are primary therapies for lung cancer and melanoma.
• Combination protocols: Specialists often combine Opdivo with Yervoy for treating stage 4 malignancies.
• Broad-spectrum drugs: Tecentriq, Bavencio, and Durvalumab are standard options for various solid tumors.
• Specialized hematology drugs: Blincyto, Besponsa, and Yescarta treat advanced lymphomas and diverse blood cancers.

Bookimed Expert Insight: Israeli oncology excellence stems from combining immunotherapy with genomic medicine. Clinics like Sourasky use Foundation One CDx genetic testing to predict drug response. Dr. Ari Raphael even uses T-Cell Repertoire sequencing to track exactly how well a drug works for your specific immune system.

Patient Consensus: Patients emphasize that molecular mutation testing for markers like PD-L1 is vital before starting Keytruda. They recommend confirming marker status early as it directly determines which immunotherapy drug will be most effective.

Israel leads global oncology research through personalized immunotherapy, genomic profiling, and advanced clinical trials at Joint Commission International-accredited centers. Institutions like Sourasky Medical Center and Sheba Medical Center integrate translational research into clinical practice. They focus on checkpoint inhibitors and overcoming treatment resistance.

• Genomic profiling: Experts use Foundation One CDx to identify specific mutations for targeted treatment plans.
• Advanced diagnostics: Researchers at Tel Aviv University developed non-invasive breathalyzer tools to detect lung cancer.
• Immunotherapy trials: Centers test drug-based checkpoint inhibitors and cellular CAR T-cell therapies for thoracic malignancies.
• Clinical technology: Facilities utilize Novalis TrueBeam STx technology to combine precision radiation with active immunotherapy.

Bookimed Expert Insight: Israel's research landscape is uniquely interconnected between clinical and academic hubs. For instance, specialists like Dr. Ari Raphael lead the National Genomic Medicine Initiative while managing lung cancer boards. This means patients often access experimental protocols faster than in other regions. Top clinics maintain high volume, treating 40,000 cancer patients annually with a 90% success rate.

Patient Consensus: Patients value the early access to mRNA technologies and active genomic medicine projects like PSIFAS. Many emphasize the importance of distinguishing between blood cancer treatments and specific lung cancer immunotherapy applications.